Mar 9, 2016 7:00am EST Tonix Pharmaceuticals Presents Pharmacokinetic Data on TNX-102 SL as a Potential Treatment for the Management of Fibromyalgia and Treatment of Post-Traumatic Stress Disorder at the ASCPT 2016 Annual Meeting
Mar 4, 2016 7:00am EST Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Programs Update
Feb 16, 2016 8:00am EST Tonix Pharmaceuticals Reports Top Line Results From Phase 2 Proof-of-Concept Clinical Study of TNX-201 in Episodic Tension-Type Headache
Feb 2, 2016 7:05am EST Tonix Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference
Dec 23, 2015 7:00am EST Tonix Pharmaceuticals Completes Enrollment in Phase 2 Clinical Trial of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD)
